Gripovac 3
inactivated influenza-A virus / swine
Table of contents
Overview
The marketing authorisation for Gripovac 3 has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Gripovac 3
|
| Agency product number |
EMEA/V/C/000157
|
| Active substance |
|
| International non-proprietary name (INN) or common name |
|
| Species |
Pigs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA03
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Merial S.A.S.
|
| Revision |
1
|
| Date of issue of marketing authorisation valid throughout the European Union |
14/01/2010
|
| Contact address |
Merial S.A.S.
29 avenue Tony Garnier 69007 Lyon France |
Product information
04/12/2014 Gripovac 3 - EMEA/V/C/000157 - R/0005
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Active immunisation of pigs from the age of 56 days onwards including pregnant sows against swine influenza caused by subtypes H1N1, H3N2 and H1N2 to reduce clinical signs and viral lung load after infection.
Onset of immunity: 7 days after primary vaccination.
Duration of immunity: 4 months in pigs vaccinated between the age of 56 and 96 days and 6 months in pigs vaccinated for the first time at 96 days and above.
Active immunisation of pregnant sows after finished primary immunisation by administration of a single dose 14 days prior to farrowing to develop high colostral immunity which provides clinical protection of piglets for at least 33 days after birth.